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Abstract
Internationally, health systems face an increasing demand for services from people living with multimorbidity. 
Multimorbidity is often associated with high levels of treatment burden. Targeting lifestyle factors that impact 
across multiple conditions may promote quality of life and better health outcomes for people with multimorbid-
ity. Motivational interviewing (MI) has been studied as one approach to supporting lifestyle behaviour change. 
A systematic review was conducted to assess the effectiveness of MI in healthcare settings and to consider its 
relevance for multimorbidity. Twelve meta-analyses pertinent to multimorbidity lifestyle factors were identified. 
As an intervention, MI has been found to have a small-to-medium statistically significant effect across a wide 
variety of single diseases and for a range of behavioural outcomes. This review highlights the need for specific 
research into the application of MI to determine if the benefits of MI seen with single diseases are also present 
in the context of multimorbidity.
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45.2% [5], respectively. Compared with single diseases, 
multimorbidity is associated with a higher demand on 
health services, including more primary care contacts, 
prescriptions, and referrals for specialized care [6–8]. 
Demands on patients are also higher, due to burden of 
illness and treatment [9]. Lack of coordination of services 
[9–11], inattention to patient preference [7,11], and the 
prevailing single-disease focus of clinical guidelines 
[2,12,13] all add to treatment burden. Applying single-
disease guidelines to multimorbidity is costly, increases 
polypharmacy, and involves prescription of unrealistic 
daily self-care activities [13,14]. Multimorbidity is a 
significant health issue and effective interventions are 
needed [13,15–19].
Research on multimorbidity interventions is limited 
[8,19,20]. A 2013 Cochrane Collaboration review 
identified only 10 randomized control trials; two of which 
Introduction
Multimorbidity is defined as the diagnosis of more 
than one long-term condition in one person [1]. 
Epidemiological research has found high prevalence 
rates for multimorbidity [2–4]. This is particularly true 
in primary care, with studies in Scotland, Australia, and 
the USA identifying rates of 23.2% [2], 37.1% [3], and 
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examined specific comorbidities [19]. Expert consensus 
recommendations emphasize supporting behaviour 
change to address lifestyle factors [19,21–23]. In Canada, 
Fortin and colleagues examined the association between 
lifestyle factors and multimorbidity in 1,196 subjects and 
found that smoking, a diet lacking fruit and vegetables, 
lack of physical activity, alcohol consumption, and 
excess weight, are all factors associated with an increased 
likelihood of multimorbidity [24]. Furthermore, the 
likelihood of multimorbidity increased with each 
additional unhealthy lifestyle factor [24]. Medication 
adherence may also be important, given its impact on 
chronic condition management [25,26]. The World 
Health Organization also promotes a greater focus on 
patient-centred skills, highlighting communication and 
support for behaviour change in chronic illness [23]. 
With its emphasis on the individual patient and focus 
on health-behaviour change, Fortin and colleagues 
suggest that motivational interviewing (MI) may be a 
useful intervention for the lifestyle factors impacting on 
multimorbidity [24].
MI has been formally defined as “…a collaborative, 
goal-oriented style of communication with particular 
attention to the language of change. It is designed to 
strengthen personal motivation for and commitment to a 
specific goal by eliciting and exploring the person’s own 
reasons for change within an atmosphere of acceptance 
and compassion” [27]. MI is characterized by the use of 
communication skills, such as open questions, reflective 
listening to express empathy, and emphasis on patient 
autonomy in a clinical session [27]. First described by 
Miller in 1983 [28], the original application of MI was 
in treatment programmes for people with addictions, 
and subsequent studies demonstrated good clinical 
outcomes [29]. More recently, MI has been seen as a 
potentially effective intervention in physical healthcare 
settings [30]. This has been accompanied by an increase 
in the publication of primary research [31] and system-
atic reviews of MI [32–37]. MI has been found to have 
a small-to-medium effect across settings and a range of 
target behaviours [33, 37–40]. Lundahl and Burke [41] 
reviewed the findings of four meta-analyses in 2009, 
and found that MI was significantly more effective than 
no treatment, and equivalent to other treatments for a 
range of behaviour-change outcomes. Given the breadth 
of application of MI, and its patient-centred focus, fur-
ther evaluation of its potential in multimorbidity care is 
warranted.
This systematic review identifies research papers of 
MI in healthcare where authors have used systematic 
review methodology to identify primary intervention 
trials and have also conducted a meta-analysis. This is 
the first systematic review of the literature to specifically 
examine meta-analyses. This systematic review has 
three objectives. Firstly, we will examine the evidence 
for MI in healthcare and specifically for multimorbidity, 
including the effectiveness of MI for addressing the 
lifestyle factors relevant to multimorbidity. Secondly, 
given the widespread impact of multimorbidity on the 
healthcare system and the recommendation to integrate 
multimorbidity intervention into existing healthcare 
[19], we will examine whether MI can be delivered 
effectively by a range of healthcare providers. Finally, 
based on this analysis of the reviews, we will consider 
and discuss the potential of MI in clinical work of 
patients with multimorbidity.
Methods
Our systematic review was guided by the Preferred 
Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) Statement [42,43]. Review criteria 
were outlined a priori. 
Inclusion criteria
Articles were included if the authors used systematic 
review methodology to identify relevant primary inter-
ventions, and also conducted a meta-analysis of the data 
from the identified primary interventions. Reviews 
were only included if participants were recruited from 
healthcare services, not criminal justice, education, or 
other sectors. We included reviews that identified stud-
ies of MI intervention, where authors of the reviews 
defined MI according to the general principles outlined 
by Miller and Rollnick [27], and used these principles 
in selecting the primary intervention papers. Included 
reviews were those that compared MI intervention with 
control, treatment as usual, or other intervention with 
behaviour change or standardized outcome measures. 
Search strategy and article selection
The search included articles published up to and 
including January 2014. Due to practical constraints, 
selection was limited to English-language articles that 
were peer reviewed and published in full. The following 
electronic databases were searched: PsycInfo, Medline, 
CINAHL, EMBASE, and Cochrane library. In addition, 
we searched the online bibliography accompanying the 
2013 Miller and Rollnick textbook [44]. Search terms 
were ‘motivational interview*’ AND [‘systematic 
review’ OR ‘meta-analysis’]. Terms included both 
subject index terms and free text. Duplicate articles were 
removed using the duplicate identification function in 
EndnoteX5 (Thomson Reuters, New York, Version X5 
for Macintosh and Windows, 2011).
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health (7), Conference proceedings (3), Not English (2), Treatment 
fidelity (2), Duplicate or reprint (2), Protocol only (2)
n=59
Abstracts screened to assess whether methodology is that of
systematic review or meta-analysis
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Review articles retrieved for detailed review of eligibility
n=134
Duplicate articles removed
n=148
Articles identified through electronic database searches:
PsycINFO (peer reviewed): 49, CINAHL (peer reviewed): 42
Medline: 66, EMBASE: 142, Cochrane Library: 45
n=344
Articles screened for relevance
n=249
Articles excluded as not systematic
review/meta-analysis
n=56
Articles excluded
Abstract for proposed systematic review (1), 
Study of MI mechanisms (1),
MI studies not included in review (7), MI not discussed 
(2), Discussion paper only (2), Clinical guideline (4), Not 
systematic review (3), Not English (1), Poster/conference 
only (5), Superseded review (1), Not relevant to 
multimorbidity lifestyle factors (7), No meta-analysis (88)
n=122
Id
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n
Additional articles included from
Miller and Rollnick (2013)
bibliography [44]
n=53
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ed Systematic reviews, also including meta-analysis
N=12
Figure 1 Flowchart of selection process for included articles using the following electronic databases: PsycINFO (database of abstracts produced 
by the American Psychological Association), CINAHL (Cumulative Index of Nursing and Allied Health Literature), Medline (Medical 
Literature Analysis and Retrieval System Online), EMBASE (Excerpta Medica dataBASE), Cochrane Library, and the bibliography by Miller 
and Rollnick [44].
The search strategy and initial screening of article titles 
was performed by K.J.M.; articles clearly not meeting eli-
gibility criteria were excluded. Abstracts were reviewed 
to determine whether a publication met the criteria for 
a systematic review or meta-analysis and if MI was an 
intervention included in the analysis. Full-text articles 
were reviewed to confirm eligibility. Uncertainty about 
inclusion of articles was resolved through discussion with 
the review team at regular meetings.
Assessment of quality of systematic reviews
All included articles were reviewed by K.J.M. using 
AMSTAR (A MeaSurement Tool to Assess systematic 
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Mean rating of all studies
Vasilaki et al. (2006) [53]
VanBuskirk and Wetherell (2014) [48]
Rubak et al. (2005) [39]
Lundahl et al. (2013) [33]
Lundahl et al. (2010) [40]
Lai et al. (2010) [34]
Hettema et al. (2005) [36]
Hettema and Hendricks (2010) [49]
Heckman et al. (2010) [50]
Easthall et al. (2013) [52]
 Burke et al. (2003) [37]
Armstrong et al. (2011) [51]
Figure 2 Rating for each of the identified systematic reviews that 
also included meta-analysis, using AMSTAR (A MeaSurement Tool to 
Assess systematic Reviews) [45].
Reviews [45]). AMSTAR is a reliable 11-item tool for 
assessing the methodological quality of systematic reviews 
[46]. AMSTAR items include the design and conduct of 
the systematic review, the presentation of review data, the 
scientific quality of the methods for formulating conclu-
sions, publication bias, and conflict of interest. A score of 
1 is allocated to each item that fully meets the specified 
criteria for each of the 11 AMSTAR items. A score of 0 
is allocated if the item is not met or if there is insufficient 
information presented in the review article to meet the 
criterion. The highest score possible using AMSTAR is 
11, with the high scores being indicative of better meth-
odology [46].
Data extraction
Effect size data were extracted for the overall efficacy of MI, 
as well as for alcohol, smoking cessation, diet and exercise, 
medication adherence, and weight interventions. Interpreta-
tion of effect sizes was guided by the benchmarks suggested 
by Cohen [47]. Information about the health conditions 
included in each review was extracted from summary tables 
and a review of the titles of trials included in each meta-
analysis. Information about clinician type, MI training, and 
treatment integrity was also extracted. Data extraction was 
undertaken by K.J.M. with uncertainty resolved through 
discussion with the review team. Accuracy of data extrac-
tion was checked independently in regular formal meetings 
between K.J.M. and D.P., and K.J.M. and J.M.G.
Results
Selection of systematic reviews 
The selection process is summarized in Figure 1. Twelve 
articles met the inclusion criteria.
Assessment of quality of systematic reviews
The included articles were assessed using AMSTAR 
(see Figure 2) [33,34,36,37,39,40,48–53]. The mean 
AMSTAR rating was 7.25 (SD=1.36). None of the 12 
articles met the criteria for items 5 [Was a list of studies 
(included and excluded) provided?] and 11 (Was the conflict of 
interest stated?). In addition, the criteria were only met 
for 5 of 12 studies for item 2 (Was there duplicate study 
selection and data extraction?) and 6 of 12 studies for item 
4 [Was the status of the publication (i.e. grey literature) used as 
an inclusion criterion?].
Systematic review characteristics and effect sizes
The characteristics of the included systematic reviews 
are summarized in Table 1 [33,34,36,37,39,40,48–53].
Table 2 summarizes the chronic conditions speci-
fied for participant groups in included systematic 
reviews [33,34,36,37,39,40,48–53]. Participant groups 
included people living with a range of conditions; 
however, no systematic review specifically examined 
multimorbidity. 
Table 3 summarizes the effect sizes, limita-
tions, and conclusions for each systematic review 
[33,34,36,37,39,40,48–53]. Small-to-medium statisti-
cally significant effect sizes were reported for the overall 
effect of MI intervention across a range of health behav-
iours relevant to multimorbidity. Overall effect sizes 
ranged from d=0.18 [95% confidence interval (CI) 0.01, 
0.37] [48] to d=0.77 (95% CI 0.35, 1.19) [36].
Clinicians delivering MI interventions
Summary information about clinicians delivering MI 
interventions for each of the 12 meta-analyses is pre-
sented in Table 4 [33,34,36,37,39,40,48–53]. 
Treatment fidelity and MI training
Table 5 presents a summary of the minimal informa-
tion available for MI training and treatment fidelity 
[33,34,36,37,39,40,48–53]. 
Discussion
Summary of main findings
We identified 12 systematic reviews that also included 
meta-analysis for MI in healthcare. We did not identify 
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a study specifically examining MI as an intervention for 
multimorbidity. It appears that MI is as effective as other 
treatments for each of the lifestyle factors relevant to 
multimorbidity, and that it can be delivered by a range 
of healthcare providers. The extent to which these find-
ings apply to the setting of multimorbidity has yet to be 
determined. 
Strengths and limitations
Overall, the included systematic reviews were of a good 
quality. Similar to other studies [55,56], some items on 
the AMSTAR tool were not met by any publication. 
Items requiring more extensive statements may be 
affected by publication parameters. This review has 
synthesized significant amounts of information, and the 
quality of the reviews supports the conclusions drawn.
This review is limited by the fact that included 
reviews evaluate the effectiveness of MI for single dis-
eases. We have examined the evidence for the lifestyle 
factors relevant to multimorbidity, in the absence of spe-
cific multimorbidity studies. We are therefore inferring 
from the available evidence about the potential of MI 
for multimorbidity; in particular, its potential to address 
lifestyle factors impacting on the health of patients with 
multimorbidity. 
Additionally, a potential limitation of this review is 
that selection was limited to English-language publica-
tions. In this case, publication bias may be ameliorated 
by statistical assessment of publication bias in 75% of the 
included systematic reviews, and searching of grey lit-
erature in 50%. There was also a lack of information 
about cost-effectiveness. The systematic review by Lai 
and colleagues identified two trials that reported infor-
mation about cost, but the information was insufficient 
to draw any conclusions [34]. While some authors of 
the included systematic reviews suggested that MI may 
be more cost-effective than other interventions as it is 
a briefer intervention [40,50,53], the need for specific 
cost–effectiveness analyses was identified as an impor-
tant consideration in future research [37,40,53]. 
Relating the findings to the existing literature
The lack of evidence for the application of MI to mul-
timorbidity intervention is not an unexpected finding. 
The Cochrane Review undertaken by Smith and col-
leagues [19] only identified 10 randomized controlled 
trials of intervention for multimorbidity and none of 
these included MI. Despite the lack of intervention trials, 
expert consensus recommendations identify patient-cen-
tred care and communication skills, promoting healthy 
behaviours, and integrating intervention into routine 
healthcare as core elements for multimorbidity interven-
tion [4,12,19,23,24]. Indeed, some of the authors of the 
included reviews propose implementing MI as an inter-
vention in routine healthcare [33,36,39,40,48,52] and 
for the multiple behaviour-change challenges inherent 
in primary care practice [48]. 
Implications for research and clinical practice
MI is a well-articulated and learnable skill [57–59] 
and appears to be a useful intervention for a range of 
health-behaviour-change targets, such as diet and 
exercise, weight management, smoking cessation, 
medication adherence, and alcohol consumption. All 
of these behaviours are relevant to people living with 
multimorbidity.
Further research may benefit from a greater focus 
on clinician proficiency, and a greater emphasis on the 
effectiveness of MI when delivered by a range of clini-
cians. Future research also needs to include treatment 
fidelity measures [37] to ensure the intervention being 
studied is indeed MI. In addition, it may also be help-
ful to use treatment fidelity measures with treatment as 
usual or comparison conditions to evaluate the degree to 
which MI can be differentiated from baseline communi-
cation styles in routine healthcare delivery [60].
Conclusion
Multimorbidity presents significant challenges to the 
people who are living with multiple conditions and 
healthcare professionals alike. MI appears to be a helpful 
approach to healthcare across a range of single diseases, 
and for health-behaviour change. Based on the exist-
ing recommendations for multimorbidity interventions 
and the findings of this review, it appears that research 
that directly examines the application of MI for working 
with people with multimorbidity is warranted. 
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